<DOC>
	<DOC>NCT00102063</DOC>
	<brief_summary>The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.</brief_summary>
	<brief_title>Aripiprazole in Adolescents With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Primary diagnosis of Schizophrenia 1 Patients diagnosed with schizoaffective disorder, major depressive disorder, delirium, or bipolar disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>